Augmented binary substitution: Single-pass cdr germlining and stabilization of therapeutic antibodies

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 50, 2015, Pages 15354-15359

  Townsend, Sue ^a   Fennell, Brian J ^a   Apgar, James R ^a   Lambert, Matthew ^a   McDonnell, Barry ^a   Grant, Joanne ^a   Wade, Jason ^a   Franklin, Edward ^a   Foy, Niall ^a   Shúilleabháin, Deirdre Ní ^a   Fields, Conor ^a   Darmanin Sheehan, Alfredo ^a   King, Amy ^a   Paulsen, Janet E ^a   Hickling, Timothy P ^a   Tchistiakova, Lioudmila ^a   Cunningham, Orla ^a   Finlay, William J J ^a   Cooper, Max D ^b  

^a PFIZER INC   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Antibody; Humanization; Immunogenicity; Paratope; Plasticity

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; COMPLEMENTARITY DETERMINING REGION; EPITOPE; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN VARIABLE REGION; PEPTIDE LIBRARY; TAU PROTEIN;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CLONE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; GENE SEQUENCE; GERM LINE; HUMAN; HUMAN CELL; IMMUNOGENICITY; PRIORITY JOURNAL; REVERTANT; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY SPECIFICITY; CELL CLONE; CHEMISTRY; COMPUTER SIMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; GERM CELL; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; MOLECULAR GENETICS; MOLECULAR MODEL; MUTATION; PEPTIDE LIBRARY; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; RAT; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CLONE CELLS; COMPLEMENTARITY DETERMINING REGIONS; COMPUTER SIMULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; GERM CELLS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE LIBRARY; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; RATS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN; TAU PROTEINS;

EID: 84950117303     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510944112     Document Type: Article

References (66)

1. Nelson AL, Dhimolea E, Reichert J.M. (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10):767-774.
2. Rader C, et al (2000) The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem 275(18):13668-13676.
3. Shih HH, et al (2012) An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition. J Biol Chem 287(53):44425-44434.
4. Miller RA, Oseroff AR, Stratte P.T., Levy R. (1983) Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62(5):988-995.
5. Harding FA, Stickler MM, Razo J, DuBridge R.B. (2010) The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs 2(3):256-265.
6. Jawa V, et al (2013) T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol 149(3):534-555.
7. Jones PT, Dear PH, Foote J, Neuberger M.S., Winter G. (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (6069):522-525.
8. Almagro JC, Fransson J. (2008) Humanization of antibodies. Front Biosci 13:1619-1633.
9. Hwang WY, Foote J. (2005) Immunogenicity of engineered antibodies. Methods 36(1):3-10.
10. Baca M, Presta LG, O'Connor SJ, Wells J.A. (1997) Antibody humanization using monovalent phage display. J Biol Chem 272(16):10678-10684.
11. Dall'Acqua WF, et al. (2005) Antibody humanization by framework shuffling. Methods 36(1):43-60.
12. Dennis MS (2010) CDR repair: A novel approach to antibody humanization. Current Trends in Monoclonal Antibody Development and Manufacturing 1(1):9-28.
13. Fransson J, et al (2010) Human framework adaptation of a mouse anti-human IL-13 antibody. J Mol Biol 398(2):214-231.
14. Hanf KJ, et al (2014) Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework. Methods 65(1): 68-76.
15. Lazar GA, Desjarlais JR, Jacinto J, Karki S., Hammond P.W. (2007) A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol 44(8):1986-1998.
16. Tan P, et al (2002) "Superhumanized" antibodies: Reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: Application to an anti-CD28. J Immunol 169(2):1119-1125.
17. Padlan EA (1991) A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 28(4-5):489-498.
18. Haidar JN, et al (2012) A universal combinatorial design of antibody framework to graft distinct CDR sequences: A bioinformatics approach. Proteins 80(3):896-912.
19. Finlay WJ, Almagro J.C. (2012) Natural and man-made V-gene repertoires for antibody discovery. Front Immunol 3:342.
20. Almagro JC, et al (2014) Second antibody modeling assessment (AMA-II). Proteins 82(8):1553-1562.
21. Bowers PM, et al (2013) Humanization of antibodies using heavy chain complementarity-determining region 3 grafting coupled with in vitro somatic hypermutation. J Biol Chem 288(11):7688-7696.
22. Sun SB, et al (2013) Mutational analysis of 48G7 reveals that somatic hypermutation affects both antibody stability and binding affinity. J Am Chem Soc 135(27): 9980-9983.
23. Bumbaca D, et al (2011) Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 3(4):376-386.
24. van Meer P.J., et al (2013) Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs 5(5):810-816.
25. van Aerts L.A., De Smet K, Reichmann G, van der Laan JW, Schneider CK (2014) Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union. MAbs 6(5):1155-1162.
26. Rosenberg AS (2006) Effects of protein aggregates: An immunologic perspective. AAPS J 8(3):E501-E507.
27. Ahmadi M, et al (2015) Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm Res 32(4): 1383-1394.
28. Finlay WJ, et al (2009) Affinity maturation of a humanized rat antibody for anti-RAGE therapy: Comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions. J Mol Biol 388(3):541-558.
29. Bernett MJ, et al (2010) Engineering fully human monoclonal antibodies from murine variable regions. J Mol Biol 396(5):1474-1490.
30. MacCallum RM, Martin AC, Thornton J.M. (1996) Antibody-antigen interactions: Contact analysis and binding site topography. J Mol Biol 262(5):732-745.
31. Almagro JC (2004) Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: Implications for the rational design of antibody repertoires. J Mol Recognit 17(2):132-143.
32. Raghunathan G, Smart J, Williams J., Almagro J.C. (2012) Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens. J Mol Recognit 25(3):103-113.
33. Vajdos FF, et al (2002) Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol 320(2):415-428.
34. Bostrom J, et al (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323 (5921):1610-1614.
35. Chailyan A, Marcatili P, Cirillo D., Tramontano A. (2011) Structural repertoire of immunoglobulin À light chains. Proteins 79(5):1513-1524.
36. North B, Lehmann A, Dunbrack R.L., Jr (2011) A new clustering of antibody CDR loop conformations. J Mol Biol 406(2):228-256.
37. Chothia C, Lesk A.M. (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196(4):901-917.
38. Martin AC, Thornton J.M. (1996) Structural families in loops of homologous proteins: Automatic classification, modelling and application to antibodies. J Mol Biol 263(5): 800-815.
39. Hötzel I., et al (2012) A strategy for risk mitigation of antibodies with fast clearance. MAbs 4(6):753-760.
40. Vugmeyster Y, et al (2010) Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys. J Transl Med 8:41.
41. Sampei Z, et al (2013) Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 8(2):e57479.
42. Li B, et al (2014) Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs 6(5): 1255-1264.
43. Wu H, et al (2005) Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 350(1): 126-144.
44. USFDA (2014) Guidance for Industry - Immunogenicity Assessment for Therapeutic Protein Products. Available at www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf.
45. Roguska MA, et al (1994) Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA 91(3):969-973.
46. Gao SH, Huang K, Tu H., Adler A.S. (2013) Monoclonal antibody humanness score and its applications. BMC Biotechnol 13:55.
47. Thullier P, Huish O, Pelat T., Martin A.C. (2010) The humanness of macaque antibody sequences. J Mol Biol 396(5):1439-1450.
48. Abhinandan KR, Martin A.C. (2007) Analyzing the "degree of humanness" of antibody sequences. J Mol Biol 369(3):852-862.
49. Yang X, et al (2013) Developability studies before initiation of process development: Improving manufacturability of monoclonal antibodies. MAbs 5(5):787-794.
50. Strohl WR (2014) Modern therapeutic antibody drug discovery technologies. Curr Drug Discov Technol 11(1):1-2.
51. Bogen B, Ruffini P. (2009) Review: To what extent are T cells tolerant to immunoglobulin variable regions? Scand J Immunol 70(6):526-530.
52. Mazor R, Tai CH, Lee B, Pastan I. (2015) Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A. J Immunol Methods 425:10-20.
53. Rader C, Cheresh DA, Barbas C.F., 3rd (1998) A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries. Proc Natl Acad Sci USA 95(15):8910-8915.
54. Baek DS, Kim Y.S. (2015) Humanization of a phosphothreonine peptide-specific chicken antibody by combinatorial library optimization of the phosphoepitope-binding motif. Biochem Biophys Res Commun 463(3):414-420.
55. King AC, et al (2011) High-throughput measurement, correlation analysis, and machine-learning predictions for pH and thermal stabilities of Pfizer-generated antibodies. Protein Sci 20(9):1546-1557.
56. Ewert S, Huber T, Honegger A., Plückthun A (2003) Biophysical properties of human antibody variable domains. J Mol Biol 325(3):531-553.
57. Knappik A, et al (2000) Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 296(1):57-86.
58. Mahon CM, et al (2013) Comprehensive interrogation of a minimalist synthetic CDR-H3 library and its ability to generate antibodies with therapeutic potential. J Mol Biol 425(10):1712-1730.
59. Prassler J, et al (2011) HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol 413(1):261-278.
60. Shi L, et al (2010) De novo selection of high-affinity antibodies from synthetic fab libraries displayed on phage as pIX fusion proteins. J Mol Biol 397(2):385-396.
61. Tiller T, et al (2013) A fully synthetic human Fab antibody library based on fixed VH/ VL framework pairings with favorable biophysical properties. MAbs 5(3):445-470.
62. Mouquet H, et al (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467 (7315):591-595.
63. Eswar N, et al (2006) Comparative protein structure modeling using Modeller. Curr Protocols Bioinformatics Chapter 5:Unit 5 6.
64. Schafer JR, Jesdale BM, George J.A., Kouttab NM, De Groot AS (1998) Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine 16(19):1880-1884.
65. Southwood S, et al (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160(7):3363-3373.
66. Koren E, et al (2007) Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 124(1):26-32.